Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Director | June 16, 2026 | June 18, 2026 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director · Chief Executive Officer | September 17, 2026 | September 21, 2026 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director · Chief Executive Officer · 10% owner | July 03, 2019 | July 09, 2019 |
| LianBioLIAN · Entity 9881 | Director | October 29, 2021 | November 09, 2021 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | March 27, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15 | Direct | 31,675 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
BridgeBio Pharma, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | 495,686 |
Last balance in matching sequence
After 2026-09-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-17 · Sale · Disposed 8,721 · Balance 496,965 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Row 2 · 2026-09-17 · Sale · Disposed 1,279 · Balance 495,686 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | 3,568,447 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,568,447 F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy NK 2026 GRAT | 750,000 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 750,000 F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 243,327 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 243,327 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Eidos Therapeutics, Inc.
Report date July 03, 2019 · Filed July 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 24,575,501 |
Reported balance
After 2019-07-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-07-03 · Purchase · Acquired 882,353 · Balance 24,575,501 F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
LianBio
Report date October 29, 2021 · Filed November 09, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy BridgeBio Pharma LLC | 5,002,792 |
Reported balance
Holding disclosure · report date 2021-10-29 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 5,002,792 F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Maze Therapeutics, Inc.
Report date March 27, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.38 · Expires 2036-03-26 | Direct | 33,417 |
Reported balance
After 2026-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-27 · Grant · Acquired 33,417 · Balance 33,417 F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 950 | $68.35 | $64,930.32 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 555,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,077 | $67.35 | $341,913.10 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 556,636 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 08, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 13,973 | $66.65 | $931,307.44 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 561,713 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 449 | $69.09 | $31,021.90 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,378,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,334 | $68.38 | $569,858.09 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,378,896 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,217 | $67.49 | $757,090.29 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,387,230 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 450 | $69.09 | $31,091.00 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 575,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,333 | $68.38 | $569,789.71 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 576,136 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,217 | $67.50 | $757,091.42 |
DisclosureSEC source: 0001470831-26-000423 · wk-form4_1778534126.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 584,469 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 20,000 | $74.60 | $1,492,076.00 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,398,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F10 · price: Represents the weighted average sale price of the shares sold from $74.27 to $75.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 10, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 20,000 | $74.60 | $1,492,096.00 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 595,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F9 · price: Represents the weighted average sale price of the shares sold from $74.26 to $75.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,800 | $75.53 | $589,123.86 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,418,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $75.18 to $76.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,128 | $74.57 | $382,379.06 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,426,247 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $74.18 to $75.145 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,072 | $73.64 | $520,801.17 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,431,375 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $73.15 to $74.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,500 | $75.55 | $566,661.00 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 615,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $75.22 to $76.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,300 | $74.60 | $395,403.32 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 623,186 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $74.19 to $75.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,200 | $73.64 | $530,239.68 |
DisclosureSEC source: 0001470831-26-000361 · wk-form4_1776117963.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 628,486 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $73.19 to $74.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:13 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 33,417 | $0.00 Strike: $30.38 | $0.00 |
DisclosureSEC source: 0001742485-26-000003 · form4-03312026_080346.xml · derivative · entry 1 Kumar Neil · CIK 0001742485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,417 Underlying: Common Stock · 33,417 shares Expires 2036-03-26 F1 · derivative.exercise_date: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 104,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000296 · wk-form4_1773952086.xml · derivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,313 Underlying: Common Stock · 104,313 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:28 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 40,570 | $0.00 Strike: $70.94 | $0.00 |
DisclosureSEC source: 0001470831-26-000296 · wk-form4_1773952086.xml · derivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,570 Underlying: Common Stock · 40,570 shares Expires 2036-03-16 F1 · derivative.exercise_date: 1/16th of the shares subject to this option vest and become exercisable on May 16, 2026, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 9,759 | $69.23 | $675,567.75 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 10 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,438,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F11 · price: Represents the weighted average sale price of the shares sold from $68.82 to $69.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,241 | $68.39 | $700,345.12 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,448,206 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F10 · price: Represents the weighted average sale price of the shares sold from $67.82 to $68.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,310 | $69.20 | $713,448.91 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 635,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F9 · price: Represents the weighted average sale price of the shares sold from $68.76 to $69.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 9,690 | $68.36 | $662,441.35 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 645,996 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $67.76 to $68.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 300 | $70.15 | $21,045.00 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,458,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $70.1 to $70.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,815 | $69.29 | $402,928.91 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,458,747 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $68.94 to $69.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 13,885 | $68.47 | $950,686.51 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,464,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $67.935 to $68.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 300 | $70.15 | $21,045.00 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 655,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $70.1 to $70.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,363 | $69.32 | $371,750.29 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 655,986 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $68.94 to $69.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 14,337 | $68.48 | $981,809.23 |
DisclosureSEC source: 0001470831-26-000275 · wk-form4_1773698710.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 661,349 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $67.935 to $68.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:32 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 602 | $72.80 | $43,826.20 |
DisclosureSEC source: 0001470831-26-000214 · wk-form4_1771882321.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,451 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F4 · price: Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:32 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,528 | $72.08 | $614,701.65 |
DisclosureSEC source: 0001470831-26-000214 · wk-form4_1771882321.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,053 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:32 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 18,923 | $71.03 | $1,344,189.63 |
DisclosureSEC source: 0001470831-26-000214 · wk-form4_1771882321.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,581 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 11,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000188 · wk-form4_1771458104.xml · derivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,645 Underlying: Common Stock · 11,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 19,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000188 · wk-form4_1771458104.xml · derivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,794 Underlying: Common Stock · 19,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 33,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000188 · wk-form4_1771458104.xml · derivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,176 Underlying: Common Stock · 33,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 30,970 | $75.25 | $2,330,492.50 |
DisclosureSEC source: 0001470831-26-000188 · wk-form4_1771458104.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,504 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,698 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 11,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000188 · wk-form4_1771458104.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 19,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000188 · wk-form4_1771458104.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 23:41 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 33,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001470831-26-000188 · wk-form4_1771458104.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,961 | $73.25 | $290,145.23 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 12 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,478,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F13 · price: Represents the weighted average sale price of the shares sold from $73.1 to $73.4 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,404 | $72.65 | $319,938.27 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 11 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,482,408 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F12 · price: Represents the weighted average sale price of the shares sold from $72.1 to $73.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,775 | $71.46 | $269,754.33 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 10 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,486,812 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F11 · price: Represents the weighted average sale price of the shares sold from $71.1 to $72.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,860 | $70.70 | $555,705.93 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 9 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,490,587 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $70.09 to $71.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,994 | $73.25 | $292,574.48 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 8 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 675,686 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F10 · price: Represents the weighted average sale price of the shares sold from $73.09 to $73.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,484 | $72.64 | $325,695.34 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 7 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 679,680 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F9 · price: Represents the weighted average sale price of the shares sold from $72.09 to $73.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,716 | $71.44 | $265,476.99 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 684,164 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F8 · price: Represents the weighted average sale price of the shares sold from $71.09 to $72.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,806 | $70.69 | $551,795.99 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 687,880 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F7 · price: Represents the weighted average sale price of the shares sold from $70.09 to $71.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,960 | $72.27 | $430,751.25 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,498,447 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F6 · price: Represents the weighted average sale price of the shares sold from $72.02 to $72.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 14,040 | $71.80 | $1,008,006.01 |
DisclosureSEC source: 0001470831-26-000118 · wk-form4_1770932392.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. Disclosed balance after: 4,504,407 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. F5 · price: Represents the weighted average sale price of the shares sold from $71.02 to $72.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.